Algernon Pharmaceuticals Inc (AGNPF)

[DannyDanboy]

Here is my take on the situation:

There seems to be a great deal of uncertainty and skepticism here regarding the SK human study. My question is why? I mean we are now 20 days in from the official announced enrollment date. Less than 3 weeks. Why would we expect an update on this so quickly?

Management doing a BioPub regarding multinational phase 2b/3 trials is totally separate imo. To me it shows further transparency and keeping us in the loop as usual. I know we would want management to also update us on where we are in SK formally but until the data results are available what would the point of this be?

Updating us on first patient dosing or letting us know trials are underway would only lead to more questions from shareholders. Questions they would not yet have the answers to (ie. How did patients respond to Ifenprodil? How many patients dosed so far? Any issues finding severe cases to dose? etc.) Why bother opening that can of worms before it's time. JMO.

It is my belief that management is simply being very cautious and waiting til there is something to actually report. Scientific data, doctor testimonials, symptom improvement charts and other hard facts to go along with anything South Korea related. Creating a news release to let us know that they did what they planned to do seems a bit redundant imo.